Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis

Overview

Journal Diabetes

Specialty Endocrinology

Date 2015 May 29

PMID 26016715

Citations 19

Authors

John D Clarke

Anika L Dzierlenga

Nicholas R Nelson

Hui Li

Samantha Werts

Michael J Goedken

Nathan J Cherrington

Affiliations

Soon will be listed here.

Abstract

Metformin is an antihyperglycemic drug that is widely prescribed for type 2 diabetes mellitus and is currently being investigated for the treatment of nonalcoholic steatohepatitis (NASH). NASH is known to alter hepatic membrane transporter expression and drug disposition similarly in humans and rodent models of NASH. Metformin is almost exclusively eliminated through the kidney primarily through active secretion mediated by Oct1, Oct2, and Mate1. The purpose of this study was to determine how NASH affects kidney transporter expression and metformin pharmacokinetics. A single oral dose of [(14)C]metformin was administered to C57BL/6J (wild type [WT]) and diabetic ob/ob mice fed either a control diet or a methionine- and choline-deficient (MCD) diet. Metformin plasma concentrations were slightly increased in the WT/MCD and ob/control groups, whereas plasma concentrations were 4.8-fold higher in ob/MCD mice compared with WT/control. The MCD diet significantly increased plasma half-life and mean residence time and correspondingly decreased oral clearance in both genotypes. These changes in disposition were caused by ob/ob- and MCD diet-specific decreases in the kidney mRNA expression of Oct2 and Mate1, whereas Oct1 mRNA expression was only decreased in ob/MCD mice. These results indicate that the diabetic ob/ob genotype and the MCD disease model alter kidney transporter expression and alter the pharmacokinetics of metformin, potentially increasing the risk of drug toxicity.

Citing Articles

Metformin: From Diabetes to Cancer-Unveiling Molecular Mechanisms and Therapeutic Strategies.

Amengual-Cladera E, Morla-Barcelo P, Moran-Costoya A, Sastre-Serra J, Pons D, Valle A Biology (Basel). 2024; 13(5).

PMID: 38785784 PMC: 11117706. DOI: 10.3390/biology13050302.

Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.

Xue H, Xing H, Wang B, Fu C, Zhang Y, Qiao X Drug Des Devel Ther. 2023; 17:1417-1432.

PMID: 37197367 PMC: 10184894. DOI: 10.2147/DDDT.S404055.

Representative Rodent Models for Renal Transporter Alterations in Human Nonalcoholic Steatohepatitis.

Frost K, Jilek J, Toth E, Goedken M, Wright S, Cherrington N Drug Metab Dispos. 2023; 51(8):970-981.

PMID: 37137719 PMC: 10353148. DOI: 10.1124/dmd.122.001133.

Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity.

Jilek J, Frost K, Jacobus K, He W, Toth E, Goedken M Acta Pharm Sin B. 2022; 11(12):3869-3878.

PMID: 35024313 PMC: 8727892. DOI: 10.1016/j.apsb.2021.05.030.

Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking.

Zou W, Shi B, Zeng T, Zhang Y, Huang B, Ouyang B Front Pharmacol. 2021; 12:746208.

PMID: 34912216 PMC: 8666590. DOI: 10.3389/fphar.2021.746208.

References

Hardwick R, Fisher C, Street S, Canet M, Cherrington N . Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos. 2011; 40(3):450-60. PMC: 3286272. DOI: 10.1124/dmd.111.041095. View

Fisher C, Lickteig A, Augustine L, Oude Elferink R, Besselsen D, Erickson R . Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol. 2009; 613(1-3):119-27. PMC: 2739623. DOI: 10.1016/j.ejphar.2009.04.002. View

Cicero A, Tartagni E, Ertek S . Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci. 2012; 8(5):907-17. PMC: 3506244. DOI: 10.5114/aoms.2012.31622. View

Dixon J, Bhathal P, OBrien P . Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121(1):91-100. DOI: 10.1053/gast.2001.25540. View

Alnouti Y, Petrick J, Klaassen C . Tissue distribution and ontogeny of organic cation transporters in mice. Drug Metab Dispos. 2005; 34(3):477-82. DOI: 10.1124/dmd.105.006932. View

Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K . Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol. 2009; 75(6):1280-6. DOI: 10.1124/mol.109.056242. View

Wang D, Jonker J, Kato Y, Kusuhara H, Schinkel A, Sugiyama Y . Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002; 302(2):510-5. DOI: 10.1124/jpet.102.034140. View

Hamad A, Khalil A, Connolly V, Ahmed M . Relationship between non-alcoholic fatty liver disease and kidney function: a communication between two organs that needs further exploration. Arab J Gastroenterol. 2013; 13(4):161-5. DOI: 10.1016/j.ajg.2012.06.010. View

Armstrong M, Adams L, Canbay A, Syn W . Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2013; 59(3):1174-97. DOI: 10.1002/hep.26717. View

10.

Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N . Metformin in non-alcoholic steatohepatitis. Lancet. 2001; 358(9285):893-4. DOI: 10.1016/s0140-6736(01)06042-1. View

11.

Ali R, Cusi K . New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009; 41(4):265-78. DOI: 10.1080/07853890802552437. View

12.

de Oliveira C, Stefano J, Siqueira E, Silva L, Mazo D, Rodrigues Lima V . Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res. 2008; 38(2):159-65. DOI: 10.1111/j.1872-034X.2007.00215.x. View

13.

Christensen M, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H . The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011; 21(12):837-50. DOI: 10.1097/FPC.0b013e32834c0010. View

14.

Graham G, Punt J, Arora M, Day R, Doogue M, Duong J . Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011; 50(2):81-98. DOI: 10.2165/11534750-000000000-00000. View

15.

Lake A, Novak P, Fisher C, Jackson J, Hardwick R, Billheimer D . Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos. 2011; 39(10):1954-60. PMC: 3186211. DOI: 10.1124/dmd.111.040592. View

16.

Nair S, Diehl A, Wiseman M, Farr Jr G, Perrillo R . Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004; 20(1):23-8. DOI: 10.1111/j.1365-2036.2004.02025.x. View

17.

Duong J, Kumar S, Kirkpatrick C, Greenup L, Arora M, Lee T . Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. Clin Pharmacokinet. 2013; 52(5):373-84. DOI: 10.1007/s40262-013-0046-9. View

18.

Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L . Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography. Kidney Blood Press Res. 2013; 37(4-5):305-10. DOI: 10.1159/000350158. View

19.

Clarke J, Hardwick R, Lake A, Lickteig A, Goedken M, Klaassen C . Synergistic interaction between genetics and disease on pravastatin disposition. J Hepatol. 2014; 61(1):139-47. PMC: 4065643. DOI: 10.1016/j.jhep.2014.02.021. View

20.

Wang D, Kusuhara H, Kato Y, Jonker J, Schinkel A, Sugiyama Y . Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol. 2003; 63(4):844-8. DOI: 10.1124/mol.63.4.844. View